| Original language | English |
|---|---|
| Pages (from-to) | 308-310 |
| Number of pages | 3 |
| Journal | Journal of Clinical Psychopharmacology |
| Volume | 40 |
| Issue number | 3 |
| DOIs | |
| State | Published - May 1 2020 |
Bibliographical note
Funding Information:This article was completed without any external funding. No commercial organizations had any role in the writing of this article for publication. In the last 3 years, J.M.K. has been a consultant for or received honoraria from Alkermes, Dainippon Sumitomo, Eli Lilly, Forum, Allergan, Genentech, H. Lundbeck, Intracellular Therapies, Janssen Pharmaceuticals, Johnson and Johnson, LB Pharmaceuticals, Merck, Minerva, Neurocrine, Otsuka, Pierre Fabre, Reviva, Roche, Sunovion, Takeda, and Teva. He has received grant support from Otsuka, Lundbeck, and Janssen and royalties from Up to Date. He has participated in advisory boards for Alkermes, Dainippon Sumitomo, Intracellular Therapies, Lundbeck, Neurocrine, Otsuka, Pierre Fabre, Takeda, and Teva. He is a Shareholder in Vanguard Research Group and LB Pharmaceuticals, Inc. In the last 3 years, G.S. and J.d.L. declare no conflicts of interest.
Funding
This article was completed without any external funding. No commercial organizations had any role in the writing of this article for publication. In the last 3 years, J.M.K. has been a consultant for or received honoraria from Alkermes, Dainippon Sumitomo, Eli Lilly, Forum, Allergan, Genentech, H. Lundbeck, Intracellular Therapies, Janssen Pharmaceuticals, Johnson and Johnson, LB Pharmaceuticals, Merck, Minerva, Neurocrine, Otsuka, Pierre Fabre, Reviva, Roche, Sunovion, Takeda, and Teva. He has received grant support from Otsuka, Lundbeck, and Janssen and royalties from Up to Date. He has participated in advisory boards for Alkermes, Dainippon Sumitomo, Intracellular Therapies, Lundbeck, Neurocrine, Otsuka, Pierre Fabre, Takeda, and Teva. He is a Shareholder in Vanguard Research Group and LB Pharmaceuticals, Inc. In the last 3 years, G.S. and J.d.L. declare no conflicts of interest.
| Funders | Funder number |
|---|---|
| Otsuka America | |
| H. Lundbeck A/S |
ASJC Scopus subject areas
- Psychiatry and Mental health
- Pharmacology (medical)
